A health products manufacturer is getting into ever deeper financial trouble and the three BDCs involved appear likely to face a debt-for-equity swap, or a realized loss, or both.
This post is for paying subscribers only
You might also like...
Jan
06
Pluralsight Inc: Remains Rated CCR 5 After Restructuring
2 min read
Dec
01
Research Now Group, LLC: Upgraded From CCR 4 to CCR 3